Grasshopper Observer
Subscribe
Sign in
Home
Disclaimer
Archive
About
To Life, To Life, aTyr
Embrace patience with a platform
Feb 27, 2024
•
Grasshopper Observer
Silence Therapeutics May Make Some Noise Soon
Name Silence Therapeutics
Feb 6, 2024
•
Grasshopper Observer
Addex: The Little CNS Therapeutics Company That Might
Name Addex Therapeutics
Feb 6, 2024
•
Grasshopper Observer
All Is Not Lost - How Annexon May Rise Again
Name Annexon
Feb 3, 2024
•
Grasshopper Observer
January 2024
Genelux: Even the insiders are fleeing
A 20 year old unremarkable oncolytic viral immunotherapy company, IPO’d at the start of 2023 lacking any notable investors, questionable science, and…
Jan 17, 2024
•
Grasshopper Observer
Iridex: A Microcap Pump Whose Air Will Run Out
Iridex: A Microcap Pump Whose Air Will Run Out
Jan 12, 2024
•
Grasshopper Observer
Anavex: A Misallocation of Capital
Anavex is a pre-commercial biotech with no viable products, studies or seeming value save for its ability to issue equity at the market
Jan 10, 2024
•
Grasshopper Observer
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts